公开(公告)号：US20210299156A1

公开(公告)日：2021-09-30

申请号：US17216528

申请日：2021-03-29

Applicant: University of Louisville Research Foundation, Inc.

Inventor： Paula J. Bates ,  Kenneth E. Palmer ,  Wajdi Abdul-Ahad ,  Michael Poirier

IPC: A61K31/711 ,  A61K45/06 ,  A61K47/69 ,  A61K47/10 ,  A61P31/14

Abstract: A method of administering an anti-nucleolin agent to a patient by delivering the anti-nucleolin agent to the mouth, lungs, throat, nose and eyes of a patient to prevent COVID-19. Compositions for administering an anti-nucleolin agent comprising a container and a formulation including an anti-nucleolin agent. The anti-nucleolin agent may be administered via an inhaler, nasal spray or eye drop.

公开(公告)号：US20200062703A1

公开(公告)日：2020-02-27

申请号：US16672481

申请日：2019-11-03

Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.

Inventor： Craig A. Grapperhaus ,  Robert M. Buchanan ,  Nicholas S. Vishnosky ,  Jason O. E. Young ,  Paula J. Bates ,  Sarah A. Andres ,  Caleb Aaron Calvary

IPC: C07C335/40 ,  C07D265/30 ,  A61P35/00

Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I) or (Ia)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.

公开(公告)号：US11679098B2

公开(公告)日：2023-06-20

申请号：US16597027

申请日：2019-10-09

Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.

Inventor： Paula J. Bates ,  Sarah A. Andres ,  Joseph A. Burlison ,  Levi Beverly ,  Nagaraju Miriyala

IPC: A61K31/045 ,  A61K31/4188 ,  A61K31/08 ,  A61K31/035 ,  A61K31/351 ,  A61K31/133 ,  A61K31/085 ,  A61K31/095 ,  A61K31/22 ,  A61K31/121

CPC classification number: A61K31/4188 ,  A61K31/035 ,  A61K31/045 ,  A61K31/08 ,  A61K31/085 ,  A61K31/095 ,  A61K31/121 ,  A61K31/133 ,  A61K31/22 ,  A61K31/351

Abstract: Some embodiments of the invention include methods of using a compound such as Formula (I), Formula (II), or I-1 (e.g., in compositions or in pharmaceutical compositions) for treating diseases (e.g., cancer such as chemo-resistant cancer or cancer-therapy-resistant cancer). Additional embodiments of the invention are also discussed herein.

公开(公告)号：US20180200385A1

公开(公告)日：2018-07-19

申请号：US15571763

申请日：2016-05-05

Applicant: University of Louisville Research Foundation, Inc.

Inventor： Mohammad Tariq Malik ,  Martin G. O'Toole ,  Paula J. Bates

IPC: A61K47/69 ,  C07K16/18 ,  C07K16/30 ,  A61P35/00 ,  A61K49/18 ,  A61K49/04 ,  C12N15/115 ,  A61K41/00

CPC classification number: A61K47/6923 ,  A61K9/0019 ,  A61K31/28 ,  A61K31/7105 ,  A61K41/0038 ,  A61K45/06 ,  A61K47/549 ,  A61K47/6929 ,  A61K49/0032 ,  A61K49/0065 ,  A61K49/0428 ,  A61K49/1875 ,  A61K49/1881 ,  A61P35/00 ,  C07K16/18 ,  C07K16/30 ,  C12N15/115 ,  A61K2300/00

Abstract: A composition comprises an anti-nucleolin agent conjugated to nanoparticles, and optionally containing gadolinium. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier. The composition enhances the effectiveness of radiation therapy, enhancing contrast in X-ray imaging techniques, and when gadolinium is present, provide cancer selective MRI contrast agents.